CA-AVIATRIX
22.2.2021 15:02:12 CET | Business Wire | Press release
Aviatrix , the cloud network platform, today announced that James Devine, formerly from AWS, has joined the company as a Principal Solutions Architect. While at AWS, Devine co-authored the AWS Certified Advanced Networking Study Guide and played an active role in defining cloud reference architectures for some of largest AWS customers. The company also recently added other cloud networking luminaries to its elite Solutions Architecture & Engineering team, including two former Microsoft Azure network specialists, with “Global Black Belt for Azure Networking,” classification; Manny Calero and Bryan Ashley (2 of only 10 people in the world that have this status), along with John Gonsalves, Citigroup’s former Global Head of Network Engineering.
Members of the Aviatrix Solutions Architecture & Engineering team share a common passion for cloud networking, security, and operational simplicity. This team fully understands each customer’s vision and challenges associated with cloud transformation, and helps organizations design and solve complex cloud networking and security problems in a simple and innovative way, the right way, the cloud way.
“I’m very excited to join the Aviatrix team,” said James Devine, Principal Solutions Architect at Aviatrix. “In my previous role as a networking specialist at AWS, I’ve actually recommended Aviatrix to numerous customers where the AWS platform alone couldn’t provide the visibility, control and multi-cloud capabilities they were looking for. I love working with customers, helping them design their cloud network strategies, and by using Aviatrix, our customers will experience a much smoother and more pleasant experience as they transition to multi-cloud.”
These significant additions to the Aviatrix team further validate the company’s cloud network platform, its MCNA (Multi-cloud Network Architecture) approach, and the rapid innovation that Aviatrix is bringing to cloud networking. As transformation to multi-cloud is quickly becoming essential for every organization, customers are demanding more advanced networking capabilities with a simple repeatable architecture that extends to multiple regions and multiple clouds. The top talent that Aviatrix is attracting is driving the future of cloud networking by bringing simplicity, security, operational efficiency, and advance controls for our customers. James, Manny, Bryan, and John, along with existing members of the Solutions Architecture & Engineering team, are playing a key role in defining product direction and helping with cloud architecture and design for some of the world’s largest brands. They’re also developing multi-cloud network training as part of the company’s well-recognized and respected “ACE Program ,” which recently surpassed 10k certified engineers in just under a year. This program is the first multi-cloud networking and security certification available to cloud practitioners, DevOps, networking staff, and security professionals.
“We’re thrilled to have James join our team,” stated Nauman Mustafa, Vice President Solutions Engineering, at Aviatrix. “Our elite group of cloud networking experts has many years of expertise in designing and managing network infrastructures. And now they’ve all joined Aviatrix with one thing in common – to provide the best cloud networking solutions and experience to our customers.”
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE ), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005214/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom